Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease

Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease Press release – No. 12 /...

Related Keywords

Germany ,Hamburg ,Denmark ,Copenhagen ,Køavn ,Ingelheim ,Rheinland Pfalz ,Ireland ,Boston ,Massachusetts ,United States ,Dublin ,Irish ,Zealand Pharma ,Carel Le Roux ,Eli Lilly ,Anna Krassowska ,Animal Health ,Investor Relations Corporate Communications ,Irish Life Health ,Johnson ,Novo Nordisk ,European Association For The Study Of Diabetes ,World Obesity Federation ,Boehringer Ingelheim ,Drug Administration ,Professor At University College ,World Health Organization ,World Heart Federation ,Annual Meeting ,European Association ,University College ,Principal Investigator ,About Overweight ,Fast Track ,Human Pharma ,Corporate Headquarters ,Investor Relations ,Global Media ,Zealand Pharma Phase ,Accessed September ,World Obesity ,Obes Rev ,Test Safety ,Adults With Non Alcoholic Steatohepatitis ,Zealand Pharma Receive ,Track Designation ,Investigational Treatment ,Markets ,